Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Objective: The aim of the present study was to investigate and compare the effects of two proton-pump inhibitors, lansoprazole (Limpidex 30 mg, Sigmatau) vs pantoprazole (Peptazol 40 mg, Boehringer Mannheim), included in a three-day antibiotic therapy regimen with azithromycin (Zitromax 500 mg, Pfiz...
| Publicado en: | European Journal of Gastroenterology & Hepatology Vol. 11; no. 3; pp. 247 - 251 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | clinical trial research randomized controlled trial Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Mar1999
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110640338&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 110640338 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0954691X 8CE jtl: European Journal of Gastroenterology & Hepatology issn: 0954691X maglogo: N pubinfo: dt: Mar1999 vid: 11 iid: 3 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 110640338 110640338 NLM10333196 110640338 10.1097/00042737-199903000-00007 NLM10333196 110640338 ppf: 247 ppct: 4 formats: tig: atl: Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. aug: au: Cammarota, Giovanni Papa, Alfredo Cianci, Rossella Cannizzaro, Oreste Armuzzi, Alessandro Gasbarrini, Antonio Addolorato, Giovanni Gasbarrini, Giovanni B. Cammarota, G Papa, A Cianci, R Cannizzaro, O Armuzzi, A Gasbarrini, A Addolorato, G Gasbarrini, G B affil: Department of Internal Medicine, Division of Gastroenterology, Catholic University SC, Rome, Italy, and bMadonna della Consolazione' Hospital, Division of Gastroenterology, Reggie Calabria, Italy sug: subj: Helicobacter Pylori Drug Effects Peptic Ulcer Drug Therapy Duodenal Ulcer Drug Therapy Antibiotics Therapeutic Use Helicobacter Infections Drug Therapy Drug Therapy, Combination Imidazoles Adverse Effects Azithromycin Administration and Dosage Prospective Studies Omeprazole Therapeutic Use Omeprazole Adverse Effects Sulfur Compounds Adverse Effects Proton Pump Inhibitors Enzyme Inhibitors Administration and Dosage Pilot Studies Middle Age Omeprazole Azithromycin Adverse Effects Gastrointestinal Agents Therapeutic Use Drug Therapy, Combination Adverse Effects Adolescence Enzyme Inhibitors Therapeutic Use Imidazoles Therapeutic Use Imidazoles Administration and Dosage Sulfur Compounds Administration and Dosage Sulfur Compounds Lansoprazole Heterocyclic Compounds Adverse Effects Heterocyclic Compounds Administration and Dosage Male Azithromycin Therapeutic Use Human Enzyme Inhibitors Adverse Effects Gastrointestinal Agents Adverse Effects Heterocyclic Compounds Therapeutic Use Gastrointestinal Agents Administration and Dosage Adult Sulfur Compounds Therapeutic Use Female Aged Omeprazole Administration and Dosage Antibiotics Administration and Dosage Antibiotics Adverse Effects Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Middle Aged: 45-64 years Adolescent: 13-18 years Adult: 19-44 years Aged: 65+ years Male Female ab: Objective: The aim of the present study was to investigate and compare the effects of two proton-pump inhibitors, lansoprazole (Limpidex 30 mg, Sigmatau) vs pantoprazole (Peptazol 40 mg, Boehringer Mannheim), included in a three-day antibiotic therapy regimen with azithromycin (Zitromax 500 mg, Pfizer) and tinidazole (Fasigin 500 mg, Pfizer).Design: Seventy consecutive, H. pylori-positive patients were randomly pre-treated with lansoprazole 30 mg o.d. (once daily) or pantoprazole 40 mg o.d. for two days, and subsequently respectively assigned to one of the two following treatment regimens, given for only three days: regimen A (LAT) comprising lansoprazole 30 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (bis in die), or regimen B (PAT) comprising pantoprazole 40 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. H. pylori status was evaluated by means of histology and rapid urease test at entry, and by 13C-urea breath test alone 8 weeks after treatment.Main Outcome Measures: Sixty-nine of the enrolled patients completed the study: 34 in the LAT group and 35 in the PAT group. One patient in the LAT group was lost to follow-up. In the LAT group, after the end of treatment, 28/34 patients were H. pylori-negative (per protocol: 82%; intention-to-treat: 80%). In the PAT group, after treatment, 29/35 patients were H. pylori-negative (per protocol and intention-to-treat: 83%). Mild or slight side-effects occurred in only one patient in the LAT group and in one in the PAT group.Conclusions: From this study there is no evidence that either of the two proton-pump inhibitors used is preferable in a three-day antibiotic regimen with azithromycin and tinidazole. The excellent side-effect and tolerability profiles, associated with acceptable eradication rates, make the two treatment regimens we tested particularly useful when patient compliance is difficult to achieve. pubtype: Academic Journal doctype: clinical trial research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|